DengyueMed Report: China's National Medical Products Administration has approved a milestone antitumor new drug—BaiZeAn (Tislelizumab Injection)—for the treatment of various advanced solid tumors, including non-small cell lung cancer (NSCLC), esophageal squamous cell carcinoma (ESCC), and hepatocellular carcinoma. This breakthrough advancement marks a key step in China's...